相关实验视频

Updated: Jan 7, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

吉尔丁静音增强了梅本达介导的抗癌活性:用于卵巢癌的组合治疗策略

Rahul Gupta¹, Yasmin Begum¹, Dipanjan Ghosh²

¹Infectious Diseases & Immunology Division, Lab-254, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata, 700032, India.

Medical oncology (Northwood, London, England)

|December 29, 2025

概括

梅本达 (MBZ) 结合吉尔丁静音显著抑制卵巢癌细胞的生长. 这种双重方法抑制了迁移,入侵和殖民地形成,为这种致命的恶性瘤提供了一种新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

卵巢癌是一种致命的妇科恶性瘤,治疗选择有限.
抗寄生虫药物梅本达 (MBZ) 显示出抗癌潜力,但其在卵巢癌中的机制尚不清楚.
吉尔丁 (CCDC88A) 是Akt信号传递和癌细胞入侵的关键调节剂,使其成为潜在的治疗点.

研究的目的:

为了研究梅本达 (MBZ) 和吉尔丁在卵巢癌中的联合作用.
阐明组合治疗有效性背后的分子机制.
为了探索MBZ和Girdin之间的结合相互作用.

主要方法:

卵巢癌细胞系 (OVCAR3,OAW42) 用MBZ和Girdin向的siRNA进行治疗.
生物化学分析评估了细胞迁移,入侵和克隆性.
免疫洗,分子对接,SIfT,DFT,PPI网络分析和KEGG通路丰富被用于机理学研究.

主要成果:

结合MBZ治疗和吉尔丁倒置显著降低了吉尔丁水平,并抑制了卵巢癌细胞迁移,入侵和殖民地形成.
分子对接证实了MBZ与吉尔丁的催化域的稳定结合.
该研究确定了关键瘤性途径的调节.

结论:

梅本达的抗癌疗效通过在卵巢癌中使用吉尔丁静音显著增强.
这种组合疗法代表了卵巢癌治疗的有希望的策略.
针对吉尔丁与MBZ一起,需要进一步调查妇科恶性瘤.

关键词:

吉尔丁吉尔丁 (Girdin Girdin) 是一个古老的城市.这是入侵.梅本达 (Mebendazole) 是一种药物.分子对接分子对接卵巢癌卵巢癌卵巢癌球形球形是指一个球形状的球体.

更多相关视频

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...